PMID- 28791400
OWN - NLM
STAT- MEDLINE
DCOM- 20180521
LR  - 20220727
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 16
IP  - 4
DP  - 2017 Oct
TI  - MicroRNA‑744 inhibits tumor cell proliferation and invasion of gastric cancer via 
      targeting brain‑derived neurotrophic factor.
PG  - 5055-5061
LID - 10.3892/mmr.2017.7167 [doi]
AB  - Gastric cancer is the fourth most common malignancy and the third leading cause 
      of cancer‑associated deaths worldwide. It has previously been demonstrated that 
      microRNAs (miRNAs) are actively involved in the pathogenesis of gastric cancer. 
      Therefore, miRNAs have been proposed as promising therapeutic targets in gastric 
      cancer patients. MiR‑744 is aberrantly expressed in different types of human 
      cancer. However, the expression pattern and biological roles of miR‑744 in 
      gastric cancer remain unknown. The present study demonstrated that miR‑744 
      expression was low in gastric cancer tissues and cell lines. Low expression 
      levels of miR‑744 was significantly correlated with lymph node metastasis, 
      invasive depth and TNM staging in gastric cancer patients. The restoration of 
      miR‑744 expression inhibited cell proliferation and invasion in vitro. 
      Bioinformatic prediction, luciferase reporter assay, reverse 
      transcription‑quantitative polymerase chain reaction and western blot analysis 
      verified that brain‑derived neurotrophic factor (BDNF) is a direct target of 
      miR‑744 in gastric cancer cells. Furthermore, BDNF was upregulated in gastric 
      cancer tissues and inversely correlated with miR‑744 expression. Furthermore, 
      enforced BDNF expression reversed the tumor‑suppressing effects of miR‑744 on the 
      proliferation and invasion of gastric cancer cells, indicating that BDNF is a 
      functional mediator of miR‑744 in gastric cancer. The present study suggests that 
      miR‑744 is a potential prognostic biomarker and treatment target in gastric 
      cancer patients.
FAU - Xu, Ai-Jun
AU  - Xu AJ
AD  - Department of Endoscope, The Cancer Hospital of Harbin Medical University, 
      Harbin, Heilongjiang 150081, P.R. China.
FAU - Fu, Li-Na
AU  - Fu LN
AD  - Department of Gastroenterology, Tianjin Fourth Central Hospital, Tianjin 300140, 
      P.R. China.
FAU - Wu, Hua-Xing
AU  - Wu HX
AD  - Department of Endoscope, The Cancer Hospital of Harbin Medical University, 
      Harbin, Heilongjiang 150081, P.R. China.
FAU - Yao, Xiao-Li
AU  - Yao XL
AD  - Department of Endoscope, The Cancer Hospital of Harbin Medical University, 
      Harbin, Heilongjiang 150081, P.R. China.
FAU - Meng, Rui
AU  - Meng R
AD  - Department of Endoscope, The Cancer Hospital of Harbin Medical University, 
      Harbin, Heilongjiang 150081, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20170804
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (3' Untranslated Regions)
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (MIRN744 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
RIN - Mol Med Rep. 2022 Sep;26(3):. PMID: 35894137
MH  - 3' Untranslated Regions
MH  - Adult
MH  - Aged
MH  - Brain-Derived Neurotrophic Factor/*genetics
MH  - Cell Line, Tumor
MH  - Cell Movement
MH  - Cell Proliferation
MH  - Computational Biology/methods
MH  - Female
MH  - Gene Expression
MH  - Genes, Reporter
MH  - Humans
MH  - Male
MH  - MicroRNAs/*genetics
MH  - Middle Aged
MH  - Neoplasm Grading
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - *RNA Interference
MH  - Stomach Neoplasms/*genetics/pathology
EDAT- 2017/08/10 06:00
MHDA- 2018/05/22 06:00
CRDT- 2017/08/10 06:00
PHST- 2017/03/20 00:00 [received]
PHST- 2017/07/28 00:00 [accepted]
PHST- 2017/08/10 06:00 [pubmed]
PHST- 2018/05/22 06:00 [medline]
PHST- 2017/08/10 06:00 [entrez]
AID - 10.3892/mmr.2017.7167 [doi]
PST - ppublish
SO  - Mol Med Rep. 2017 Oct;16(4):5055-5061. doi: 10.3892/mmr.2017.7167. Epub 2017 Aug 
      4.